Cargando…
Development of a unique anti-AML immune therapy consisting of cord blood HSCT and cord blood stem cell-derived dendritic cell (CB-DC) vaccination
Autores principales: | de Haar, Colin, Plantinga, Maud, Blokland, Nina, Spel, Lotte, Boes, Marianne, Nierkens, Stefan, Boelens, Jaap Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990352/ http://dx.doi.org/10.1186/2051-1426-1-S1-P206 |
Ejemplares similares
-
Clinical Grade Production of Wilms’ Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation
por: Plantinga, Maud, et al.
Publicado: (2020) -
Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation
por: Spel, Lotte, et al.
Publicado: (2013) -
Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells Specifically Originate from CD115-Expressing Precursors
por: Plantinga, Maud, et al.
Publicado: (2019) -
Efficient lentiviral transduction method to gene modify cord blood CD8(+) T cells for cancer therapy applications
por: Lo Presti, Vania, et al.
Publicado: (2021) -
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
por: Plantinga, Maud, et al.
Publicado: (2014)